Viktor Umansky

List of Publications by Citations

Source: https://exaly.com/author-pdf/7304637/viktor-umansky-publications-by-citations.pdf
Version: 2024-04-19

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99 papers	7,242 citations	44 h-index	84 g-index
108 ext. papers	9,417 ext. citations	7.9 avg, IF	6 L-index

#	Paper	IF	Citations
99	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nature Communications*, **2016**, 7, 12150	17.4	1388
98	Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. *Frontiers in Immunology*, **2018**, 9, 398	8.4	274
97	Bone marrow as a priming site for T-cell responses to blood-borne antigen. *Nature Medicine*, **2003**, 9, 1151-7	50.5	262
96	Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. *Journal of Immunology*, **2012**, 189, 5602-11	5.3	261
95	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. *Frontiers in Immunology*, **2018**, 9, 1310	8.4	260
94	Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 17111-6	11.5	255
93	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. *Clinical Cancer Research*, **2015**, 21, 5453-9	12.9	237
92	Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. *British Journal of Cancer*, **2019**, 120, 16-25	8.7	235
91	CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. *Molecular Therapy*, **2014**, 22, 1949-59	11.7	212
90	The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. *Vaccines*, **2016**, 4,	5.3	187
89	Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. *OncoImmunology*, **2015**, 4, e1008371	7.2	182
88	Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. *Journal of Biological Chemistry*, **2013**, 288, 36691-702	5.4	167
87	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature*, **2021**, 592, 450-456	50.4	164
86	Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. *Journal of Immunology*, **2013**, 190, 2464-71	5.3	156
85	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. *Journal of Clinical Investigation*, **2018**, 128, 5505-5516	15.9	120
84	Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. *International Journal of Cancer*, **2013**, 133, 98-107	7.5	116
83	Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. *International Journal of Cancer*, **2015**, 136, 2352-60	7.5	112

82	Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. *Cancer Immunology, Immunotherapy*, **2019**, 68, 687-697	7.4	103
81	Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. *Journal of Immunotoxicology*, **2012**, 9, 292-300	3.1	98
80	Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. *Journal of Investigative Dermatology*, **2012**, 132, 1239-46	4.3	96
79	Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. *Journal of Clinical Investigation*, **2004**, 114, 67-76	15.9	94
78	Tumor microenvironment and myeloid-derived suppressor cells. *Cancer Microenvironment*, **2013**, 6, 169-77	6.1	90
77	Melanoma-induced immunosuppression and its neutralization. *Seminars in Cancer Biology*, **2012**, 22, 319-26	12.7	89
76	von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. *Blood*, **2015**, 125, 3153-63	2.2	86
75	CCR5 Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. *Cancer Research*, **2018**, 78, 157-167	10.1	82
74	Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 777-787	10.2	79
73	Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. *Journal of Investigative Dermatology*, **2013**, 133, 1610-9	4.3	79
72	SOX2 in development and cancer biology. *Seminars in Cancer Biology*, **2020**, 67, 74-82	12.7	71
71	Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. *OncoImmunology*, **2015**, 4, e998519	7.2	67
70	Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. *Clinical Cancer Research*, **2009**, 15, 4382-90	12.9	63
69	Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. *Seminars in Cancer Biology*, **2014**, 28, 51-7	12.7	58
68	Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. *Cancer Research*, **2008**, 68, 9451-8	10.1	58
67	Opposing roles of eosinophils in cancer. *Cancer Immunology, Immunotherapy*, **2019**, 68, 823-833	7.4	57
66	CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. *Cancer Immunology, Immunotherapy*, **2017**, 66, 1015-1023	7.4	56
65	Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation. *Cancer Research*, **2016**, 76, 4359-71	10.1	54

64	CCR5 Directs the Mobilization of CD11bGr1Ly6C Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development. *Cell Reports*, **2017**, 21, 2212-2222	10.6	52
63	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). *OncoImmunology*, **2017**, 6, e1326440	7.2	51
62	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. *Cancer Research*, **2019**, 79, 4715-4728	10.1	51
61	Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. *Cancer Immunology, Immunotherapy*, **2012**, 61, 275-282	7.4	50
60	Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. *Journal of Immunology*, **2009**, 183, 6330-7	5.3	50
59	Myeloid-derived suppressor cells and tumor escape from immune surveillance. *Seminars in Immunopathology*, **2017**, 39, 295-305	12	49
58	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. *Journal of Clinical Investigation*, **2016**, 126, 921-37	15.9	48
57	Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation **2020**, 8,		46
56	Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. *Journal of Immunotoxicology*, **2012**, 9, 275-81	3.1	45
55	Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. *OncoImmunology*, **2018**, 7, e1442167	7.2	44
54	Extracellular adenosine metabolism in immune cells in melanoma. *Cancer Immunology, Immunotherapy*, **2014**, 63, 1073-80	7.4	42
53	Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection. *OncoImmunology*, **2016**, 5, e1204506	7.2	36
52	Targeting SOX2 in anticancer therapy. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 983-991	6.4	36
51	SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. *International Journal of Cancer*, **2018**, 143, 3131-3142	7.5	34
50	Myeloid-derived suppressor cells in malignant melanoma. *JDDG - Journal of the German Society of Dermatology*, **2014**, 12, 1021-7	1.2	33
49	Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. *Cancer Research*, **2006**, 66, 5997-6001	10.1	29
48	Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. *International Journal of Cancer*, **2019**, 145, 3462-3477	7.5	28
47	Interactions among myeloid regulatory cells in cancer. *Cancer Immunology, Immunotherapy*, **2019**, 68, 645-660	7.4	28

46	IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. *Cellular Immunology*, **2021**, 359, 104254	4.4	26
45	Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. *Stem Cell Reports*, **2017**, 8, 1379-1391	8	25
44	IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma **2020**, 8,		25
43	Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. *Oncotarget*, **2016**, 7, 68527-68545	3.3	24
42	Effect of artesunate on immune cells in ret-transgenic mouse melanoma model. *Anti-Cancer Drugs*, **2009**, 20, 910-7	2.4	23
41	Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. *International Journal of Cancer*, **2015**, 137, 2607-17	7.5	22
40	Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. *OncoImmunology*, **2020**, 9, 1727116	7.2	21
39	Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. *Oncotarget*, **2014**, 5, 4516-28	3.3	20
38	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	20
37	Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. *Stem Cells*, **2016**, 34, 832-46	5.8	18
36	Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation. *International Journal of Cancer*, **2018**, 143, 2962-2972	7.5	17
35	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF□Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. *Journal of Immunotherapy*, **2016**, 39, 343-354	5	17
34	The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment. *Wspolczesna Onkologia*, **2018**, 22, 7-13	1	17
33	Predictive immune markers in advanced melanoma patients treated with ipilimumab. *OncoImmunology*, **2016**, 5, e1158901	7.2	16
32	T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma. *Cancers*, **2012**, 4, 490-503	6.6	14
31	T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells. *British Journal of Cancer*, **2020**, 122, 1023-1036	8.7	13
30	Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. *OncoImmunology*, **2020**, 9, 1744946	7.2	13
29	Myeloide Suppressorzellen (MDSC) beim malignen Melanom. *JDDG - Journal of the German Society of Dermatology*, **2014**, 12, 1021-1027	1.2	13

28	Comment on "Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b(+)Gr1(+) cells". *Journal of Immunology*, **2012**, 188, 2929-30; author reply 1930	5.3	11
27	Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening. *OncoImmunology*, **2017**, 6, e1258503	7.2	10
26	ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. *Cell Death and Disease*, **2019**, 10, 760	9.8	10
25	Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases. *PLoS ONE*, **2014**, 9, e96799	3.7	10
24	Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. *Cancers*, **2019**, 11,	6.6	9
23	Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. *OncoImmunology*, **2018**, 7, e1445457	7.2	9
22	Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells. *Pigment Cell and Melanoma Research*, **2013**, 26, 457-63	4.5	9
21	Dormant tumor cells interact with memory CD8 T cells in RET transgenic mouse melanoma model. *Cancer Letters*, **2020**, 474, 74-81	9.9	8
20	Tumor-Specific Regulatory T Cells from the Bone Marrow Orchestrate Antitumor Immunity in Breast Cancer. *Cancer Immunology Research*, **2019**, 7, 1998-2012	12.5	8
19	Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	8
18	Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression. *Cancers*, **2021**, 13,	6.6	8
17	Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma. *Molecular Therapy - Oncolytics*, **2020**, 18, 83-99	6.4	7
16	Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
15	New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment. *OncoImmunology*, **2012**, 1, 765-767	7.2	5
14	mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. *OncoImmunology*, **2016**, 5, e1160183	7.2	3
13	Fighting infant infections with myeloid-derived suppressor cells. *Journal of Clinical Investigation*, **2019**, 129, 4080-4082	15.9	3
12	Complex Formation with Monomeric □Tubulin and Importin 13 Fosters c-Jun Protein Stability and Is Required for c-Jun□s Nuclear Translocation and Activity. *Cancers*, **2019**, 11,	6.6	3
11	Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. *Cellular Immunology*, **2021**, 360, 104274	4.4	3

10	Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization. *International Journal of Cancer*, **2021**, 149, 1628-1638	7.5	2
9	Depletion and Maturation of Myeloid-Derived Suppressor Cells in Murine Cancer Models. *Methods in Molecular Biology*, **2021**, 2236, 67-75	1.4	2
8	A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival. *International Journal of Cancer*, **2019**, 144, 909-921	7.5	1
7	FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor. *International Journal of Cancer*, **2021**, 149, 657-674	7.5	1
6	Ret mouse very large tumors (VLTs) display altered ratios of infiltrating memory to naive T cells: Roles in tumor expansion. *Pathophysiology*, **2016**, 23, 211-20	1.8	1
5	STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. **2022**, 10,		1
4	Perspective Escape from destruction: how cancer-derived EVs are protected from phagocytosis. *Trillium Extracellular Vesicles*, **2020**, 2, 60-64	0.2	0
3	Involvement of platelet-derived VWF in metastatic growth of melanoma in the brain.. *Neuro-Oncology Advances*, **2021**, 3, vdab175	0.9	0
2	Characterization and longitudinal monitoring of melanoma growth in ret-transgenic mice using a single-sequence MRI protocol. *Experimental Dermatology*, **2012**, 21, 837-41	4	
1	ChemoImmunoModulation: Focus on Myeloid Regulatory Cells **2013**, 603-619		